249 related articles for article (PubMed ID: 25596698)
21. PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment.
Zhu X; Ji M; Han Y; Guo Y; Zhu W; Gao F; Yang X; Zhang C
Int J Oncol; 2017 Mar; 50(3):835-846. PubMed ID: 28197632
[TBL] [Abstract][Full Text] [Related]
22. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1.
Peluso JJ; Liu X; Saunders MM; Claffey KP; Phoenix K
J Clin Endocrinol Metab; 2008 May; 93(5):1592-9. PubMed ID: 18319313
[TBL] [Abstract][Full Text] [Related]
23. Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule.
Ahmed IS; Rohe HJ; Twist KE; Mattingly MN; Craven RJ
J Pharmacol Exp Ther; 2010 May; 333(2):564-73. PubMed ID: 20164297
[TBL] [Abstract][Full Text] [Related]
24. In vitro inhibition of SKOV-3 cell migration as a distinctive feature of progesterone receptor membrane component type 2 versus type 1.
Albrecht C; Huck V; Wehling M; Wendler A
Steroids; 2012 Dec; 77(14):1543-50. PubMed ID: 23064006
[TBL] [Abstract][Full Text] [Related]
25. Modulation of telomerase and signal transduction proteins by hexyl-ALA-photodynamic therapy (PDT) in human doxorubicin resistant cancer cell models.
Chu ES; Yow CM
Photodiagnosis Photodyn Ther; 2012 Sep; 9(3):243-55. PubMed ID: 22959804
[TBL] [Abstract][Full Text] [Related]
26. Identification of up- and down-regulated proteins in doxorubicin-resistant uterine cancer cells: reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance.
May EW; Lin ST; Lin CC; Chang JF; Hung E; Lo YW; Lin LH; Hu RY; Feng CL; Lin DY; Wu SB; Lee WC; Lyu KW; Chou HC; Chan HL
Pharmacol Res; 2014 Dec; 90():1-17. PubMed ID: 25242635
[TBL] [Abstract][Full Text] [Related]
27. Monitoring incorporation, transformation and subcellular distribution of N-l-leucyl-doxorubicin in uterine sarcoma cells using capillary electrophoretic techniques.
Wang Y; Arriaga EA
Cancer Lett; 2008 Apr; 262(1):123-32. PubMed ID: 18194838
[TBL] [Abstract][Full Text] [Related]
28. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
29. Effects of photoactivated 5-aminolevulinic acid hexyl ester on MDR1 over-expressing human uterine sarcoma cells.
Chu ES; Yow CM; Shi M; Ho RJ
Toxicol Lett; 2008 Sep; 181(1):7-12. PubMed ID: 18625294
[TBL] [Abstract][Full Text] [Related]
30. Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2.
Zhang C; Zhao Y; Zeng B
Cancer Biomark; 2012; 12(4):155-67. PubMed ID: 23568006
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
[TBL] [Abstract][Full Text] [Related]
32. S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling.
Ahmed IS; Chamberlain C; Craven RJ
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):361-70. PubMed ID: 22292588
[TBL] [Abstract][Full Text] [Related]
33. Allopurinol, furosemide and a phytotherapeutic agent (Bazoton uno) reverse P-glycoprotein-mediated doxorubicin resistance in human uterine sarcoma MES-SA/Dx5 cells: a novel therapeutic perspective.
Angelini A; Centurione MA; Di Pietro R; Centurione L
J Biol Regul Homeost Agents; 2019 May-Jun,; 33(3):991-997. PubMed ID: 31162035
[No Abstract] [Full Text] [Related]
34. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.
Aouali N; El Btaouri H; Dumontet C; Eddabra L; Malagarie-Cazenave S; Madoulet C; Morjani H
Oncol Rep; 2011 Apr; 25(4):1161-7. PubMed ID: 21318225
[TBL] [Abstract][Full Text] [Related]
35. Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA.
Harker WG; Sikic BI
Cancer Res; 1985 Sep; 45(9):4091-6. PubMed ID: 4028002
[TBL] [Abstract][Full Text] [Related]
36. Different effects of magnetic field on drug activity in human uterine sarcoma cell lines MES-SA and MES-SA/Dx5.
Shibaki R; Kakikawa M
Electromagn Biol Med; 2022 Jul; 41(3):343-351. PubMed ID: 35793396
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5.
Larroque-Lombard AL; Todorova M; Golabi N; Williams C; Jean-Claude BJ
J Med Chem; 2010 Mar; 53(5):2104-13. PubMed ID: 20151639
[TBL] [Abstract][Full Text] [Related]
38. Nuclear proteomics with XRCC3 knockdown to reveal the development of doxorubicin-resistant uterine cancer.
Chang JF; Lin ST; Hung E; Lu YL; Soon May EW; Lo YW; Chou HC; Chan HL
Toxicol Sci; 2014 Jun; 139(2):396-406. PubMed ID: 24675091
[TBL] [Abstract][Full Text] [Related]
39. Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5.
Choi JS; Kang NS; Min YK; Kim SH
Phytother Res; 2010 Jul; 24(7):1042-6. PubMed ID: 19960428
[TBL] [Abstract][Full Text] [Related]
40. Protein kinase C isoform expression and activity alter paclitaxel resistance in vitro.
Chen L; Burger RA; Zaunbrecher GM; Cheng H; Lincoln AJ; Mallarino MC; Monk BJ; Khan SA
Gynecol Oncol; 1999 Feb; 72(2):171-9. PubMed ID: 10021296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
